Abstract
In animal model systems, the outcome of chemotherapy depends upon drug dose, tumor sensitivity, and tumor burden. In animals, optimum treatment can be determined by treating beyond lethal toxicity. This is not possible in humans, where attempts to define optimum treatment have resulted in many schedules and combinations, and attempts to avoid serious toxicity have produced many schemes to reduce doses and delay treatment. However, these schedules and schemes have obscured dose-response relationships and have led to confusion. Dose-response relationships can be rediscovered and the confusion can be cleared by expressing all treatments in terms of how much drug is given per unit time. This is dose intensity (Green and Dawson 1980). Dose intensity may be calculated from intended drug doses (“projected dose intensity”) or from doses received after reductions and delays because of toxicity (“received dose intenstiy”) (Hryniuk and Bush 1984).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Beretta G, Tabiadon D, Tedeschi L et al. (1986) Front line treatment with CMF variations for advanced breast carcinoma. A randomized study. Proc Am Soc Clin Oncol 5: 77
Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304: 10–15
Carde P, MacKintosh FP, Rosenberg SA (1983) A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. J Clin Oncol 1: 146–153
Carmo-Pereira J, Costa FO, Henriques V et al. (1986 a) A randomized trial of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer. Cancer Chemother Pharmacol 17: 87–90
Carmo-Pereira J, Costa FO, Henriques V et al. (1986b) Advanced breast carcinoma: a comparison of two dose levels of Adriamycin. Proc Am Soc Clin Oncol 5: 56
Cooper RG, Holland JF, Glidewell O (1979) Adjuvant chemotherapy of breast cancer. Cancer 44: 793–8
Coppin CML (1987) The description of chemotherapy delivery: options and pitfalls. Semin Oncol 14 (4): 34–42
Goodyear M, Hryniuk W, Clark D et al. (1985) Relationship of dose intensity (DI) to outcome in chemotherapy of advanced breast carcinoma. Proc Am Soc Clin Oncol 4: 61
Green J A, Dawson AA (1980) Measurement of drug dosage intensity in MVPP therapy in Hodgkin’s disease. Br J Clin Pharmacol 9: 511–514
Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2 (11): 1281–8
Hryniuk W, Levine M (1986) Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast carcinoma. J Clin Oncol 4: 1162–1170
Hryniuk W (1987) Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 14: 65–74
Hryniuk W, Bonadonna G, Valagussa P ( 1987 a) The effect of dose intensity in adjuvant chemotherapy. In: Jones SE, Salmon SE (eds) Adjuvant therapy of cancer, vol 5. Grune and Stratton, Orlando, Florida, pp 13–23
Hryniuk W, Figueredo A, Goodyear M (1987 b) Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin Oncol 14, (4): 3–11
Ludwig Breast Cancer Study Group (1985) A randomized trial of adjuvant combination chemotherapy with or without prednisone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res 45: 4454–4459
Nissen-Meyer R, Kjellgren K, Malmio K et al. (1978) Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy for breast cancer. The Scandinavian Adjuvant Chemotherapy Study Group (SACSG) project. Cancer 41: 2088–2098
Pater JL (1987) Implications of dose intensity for cancer clinical trials. Semin Oncol 14, (4),
Suppl 4 (December)]: 1–2
Samson JK, Rivkin SE, Jones SE et al. (1984) Dose-response and dose-survival advantage for high versus low-dose cisplatin combined with vinblastine and bleomycin in disseminated testicular cancer. A Southwest Oncology Group (SWOG) project. Cancer 53: 1029–1035
Tancini G, Bonadonna G, Valagussa P et al. (1983) Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1: 2–10
Tannock IF, Boyd NF, Perrault DJ (1987) Randomized trial of two doses of CMF chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 6: 50
Tormey DC, Gelman R, Band PR (1982) Comparison of induction chemotherapies for metastatic breast cancer. Cancer 50: 1235–1244
Wood WC (1983) Cancer and Leukemia Group B adjuvant chemotherapy trials in postmastectomy breast cancer patients. Breast Cancer Res Treat 3: 39–43
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin · Heidelberg
About this paper
Cite this paper
Hryniuk, W.M. (1989). Correlation of Dose Intensity and Prognosis in Adjuvant Chemotherapy: An Extended Controversy. In: Senn, HJ., Goldhirsch, A., Gelber, R.D., Osterwalder, B. (eds) Adjuvant Therapy of Primary Breast Cancer. Recent Results in Cancer Research, vol 115. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-83337-3_3
Download citation
DOI: https://doi.org/10.1007/978-3-642-83337-3_3
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-83339-7
Online ISBN: 978-3-642-83337-3
eBook Packages: Springer Book Archive